An open-label, multi-center, global, rollover study for patients who have previously been treated with capmatinib (INC280) as monotherapy or in combination in a Novartis Sponsored trial

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-510948-31-00

Acronym

CINC280A2X02B

Enrollment

Registered

2024-06-12

Start date

2017-07-04

Completion date

Unknown

Last updated

2025-12-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cMET-dependent malignancies

Brief summary

Safety: Frequency and severity of AEs/SAEs

Interventions

DRUGGEFITINIB

DRUGEGF816

DRUGINC280

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Safety: Frequency and severity of AEs/SAEs	—

Countries

Belgium, Germany, Italy

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026